ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$177.53M

FY 2025 · Annual

Net Income

-$166.31M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.43M30.43M64.88M79M153.35M
Selling, General & Admin2.26M6.47M9.71M15.3M24.18M
Operating Expenses8.7M36.91M74.59M94.31M177.53M
Depreciation & Amortization036.91M000
EBITDA(51.61M)0(69.33M)(80.49M)(166.31M)
EBITDA Margin—————
Operating Income(8.7M)(36.91M)(74.59M)(94.31M)(177.53M)
Operating Margin—————
Interest Income005.26M13.82M11.23M
Interest Expense00000
Other Income / Expenses(42.91M)05.26M13.82M11.23M
Income Before Tax(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Net Margin—————
EPS (Basic)(40.44)(1.10)(2.17)(2.56)(4.32)
EPS (Diluted)(40.44)(1.10)(2.17)(2.56)(4.32)
Weighted Avg Shares1.28M33.49M31.96M31.47M38.46M
Weighted Avg Shares (Diluted)1.28M33.49M31.96M31.47M38.46M

AVBP Earnings Waterfall · TTM

NASDAQ:AVBP · Revenue to Net Income

Key Ratios

EPS$-3.53
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.8
P/S Ratio0.0

Analysis

$0 of revenue converted into -$145.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.53, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 2, 2026
8-KCurrent reportOct 26, 2026

How much revenue does AVBP generate?

ArriVent BioPharma, Inc. Common Stock (AVBP) reported $0.00 of revenue in fiscal 2025.

Is AVBP profitable?

ArriVent BioPharma, Inc. Common Stock (AVBP) reported -$166.31M of net income.